Celsion Corporation with ticker code (CLSN) now have 2 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 5 and 4 calculating the average target price we see 4.5. With the stocks previous close at 2.26 this indicates there is a potential upside of 99.1%. There is a 50 day moving average of 1.61 and the 200 day moving average is 0.94. The market capitalisation for the company is $161m. Visit the company website at: http://www.celsion.com
Celsion Corporation, an integrated development clinical stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.
